Skip to Content

SHARE

Clinical Trials Details

Recurrent or Persistent Low-Grade Serous Cancer of the Ovary, Fallopian Tube or Primary Peritoneum

A Study of MEK162, Recurrent or Persistant Low-Grade Serous Chemotherapy of the Ovary, Fallopian Tube or Primary Peritoneum

Objective

Phase 3 randomized,  open-label study will evaluate MEK 162 vs physician choice of selected chemotherapies in patients with low-grade serous carcinoma of the ovaries, fallopian tubes or primary peritneal who have recurrent or persistent disease following:

  • at least 1 prior platinum-based chemotherapy
  • no more than 3 prior lines of chemotherapy
  • Central pathology review of patient histology tumor specimen
IRB Protocol Number
ARRAY-162-311
Principal Investigator(s)
Randall Gibb, MD
Sponsor(s)
Array BioPharma Inc.
Contact
Judy Miller, RN CCRP at 406-435-7482
or jmiller4@billingsclinic.org

Location

  • Billings Clinic Hospital Fountain Courtyard - South of the Hospital Cafeteria
    2750 9th Ave North
    Billings, MT 59101